Nordfarma - Company finances
|
EUR
|
2019
From: 2019-03-25
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 264,800 | 820,916 | 2,356,465 | 2,178,690 | 2,371,333 | 2,778,795 | 1,522,554 |
| Profit before tax | 13,350 | 48,598 | 280,450 | 365,641 | 301,671 | 178,123 | -174,670 |
| Net profit | 13,350 | 41,036 | 237,944 | 310,414 | 255,229 | 151,581 | -175,210 |
| Equity | 15,850 | 56,886 | 294,830 | 605,244 | 813,415 | 964,996 | 485,079 |
| Liabilities | 7,400 | 33,027 | 238,723 | 261,991 | 259,428 | 209,574 | 117,283 |
| Non-current assets | 0 | 0 | 0 | 0 | 79,097 | 64,931 | 50,764 |
| Current assets | 23,248 | 89,911 | 533,551 | 867,233 | 992,104 | 1,108,042 | 549,915 |
| Total assets | 23,248 | 89,911 | 533,551 | 867,233 | 1,071,201 | 1,172,973 | 600,679 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 56,533 | - | - |
| Social insurance contributions | - | - | - | - | 441 | 6,620 | 9,041 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +210.0% | +187.1% | -7.5% | +8.8% | +17.2% | -45.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 57.4% | 45.6% | 44.6% | 35.8% | 23.8% | 12.9% | -29.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 84.2% | 72.1% | 80.7% | 51.3% | 31.4% | 15.7% | -36.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.0% | 5.0% | 10.1% | 14.2% | 10.8% | 5.5% | -11.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.0% | 5.9% | 11.9% | 16.8% | 12.7% | 6.4% | -11.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.6 | 0.8 | 0.4 | 0.3 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 132,400 | 298,515 | 883,663 | 1,045,788 | 769,089 | 641,265 | 338,345 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nordfarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-11-18 | 2025-11-18 | 30.65 |
| 2024-07-24 | 2024-08-01 | 349.39 |
| 2024-07-18 | 2024-07-23 | 343.80 |
| 2024-07-16 | 2024-07-17 | 820.80 |
| 2024-06-19 | 2024-07-15 | 170.10 |
| 2024-06-18 | 2024-06-18 | 440.77 |
| 2024-05-21 | 2024-05-28 | 345.91 |
| 2024-05-16 | 2024-05-20 | 828.07 |
| 2024-04-23 | 2024-05-15 | 174.61 |
| 2024-04-17 | 2024-04-22 | 172.50 |
| 2024-04-16 | 2024-04-16 | 652.09 |
| 2024-03-18 | 2024-03-25 | 172.50 |
| 2024-02-19 | 2024-02-28 | 170.10 |
| 2024-01-16 | 2024-01-30 | 85.32 |
| 2023-12-18 | 2024-01-09 | 2.22 |
| 2023-11-16 | 2023-12-13 | 2.22 |
| 2023-10-25 | 2023-11-13 | 2.22 |
| 2023-09-18 | 2023-09-28 | 154.62 |
| 2023-08-17 | 2023-08-28 | 158.96 |
| 2023-07-31 | 2023-08-15 | 2.16 |
| 2023-07-28 | 2023-07-30 | 156.78 |
| 2023-07-26 | 2023-07-27 | 154.62 |
| 2023-07-24 | 2023-07-25 | 156.83 |
| 2023-07-18 | 2023-07-23 | 154.62 |
| 2023-06-16 | 2023-07-04 | 154.62 |
| 2023-05-16 | 2023-05-25 | 158.54 |
| 2023-05-04 | 2023-05-14 | 0.64 |
| 2023-05-02 | 2023-05-03 | 152.38 |
| 2023-04-26 | 2023-04-28 | 152.38 |
| 2023-04-19 | 2023-04-25 | 151.74 |
| 2023-04-18 | 2023-04-18 | 584.62 |
| 2023-03-16 | 2023-03-19 | 426.73 |
| 2022-09-16 | 2022-09-20 | 399.99 |
| 2022-04-28 | 2022-05-04 | 224.35 |
| 2022-04-19 | 2022-04-27 | 222.28 |
| 2022-03-16 | 2022-04-14 | 222.67 |
| 2022-02-17 | 2022-03-15 | 0.39 |
| 2022-01-31 | 2022-02-13 | 0.39 |
| 2021-12-30 | 2022-01-12 | 1.36 |
| 2021-12-16 | 2021-12-29 | 1.40 |
| 2021-11-16 | 2021-12-13 | 1.36 |
| 2021-11-05 | 2021-11-14 | 1.36 |
| 2021-10-18 | 2021-10-25 | 118.16 |
| 2021-09-16 | 2021-09-26 | 118.19 |
Nordfarma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-02 | 2026-04-09 | 896.34 |
| 2026-03-27 | 2026-04-01 | 13.99 |
| 2026-03-24 | 2026-03-26 | 4130.9 |
| 2026-03-22 | 2026-03-23 | 7154.55 |
| 2026-03-20 | 2026-03-21 | 7158.67 |
| 2026-03-19 | 2026-03-19 | 3.92 |
| 2026-03-16 | 2026-03-17 | 1353.22 |
| 2026-03-08 | 2026-03-15 | 1350.07 |
| 2026-02-03 | 2026-02-16 | 2.41 |
| 2026-01-27 | 2026-01-27 | 1780.64 |
| 2025-12-20 | 2025-12-22 | 1.88 |
| 2025-12-18 | 2025-12-19 | 2.04 |
| 2025-11-24 | 2025-11-25 | 612.35 |
| 2025-11-06 | 2025-11-09 | 23.84 |
| 2025-11-02 | 2025-11-05 | 905.5 |
| 2025-10-26 | 2025-11-01 | 902.15 |
| 2025-10-25 | 2025-10-25 | 1943.76 |
| 2025-10-24 | 2025-10-24 | 1061.41 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Nordfarma, UAB (code 305088480) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €1.52M and reported a net loss of €175.2K, corresponding to a profit margin of -11.5%. Revenue declined by 45.2% year on year, following a rise from €2.37M in 2023 to €2.78M in 2024 before the drop in 2025. Profitability followed a similar pattern: net profit of €255.2K in 2023 decreased to €151.6K in 2024 and then turned negative in 2025. At year-end 2025, total assets were €600.7K, equity €485.1K and liabilities €117.3K. The equity ratio stood at 80.8%, debt-to-equity at 0.24, and asset turnover at 2.53x. The business also generated €380.6K of revenue per employee, while profit per employee was -€43.8K, reflecting the weaker 2025 operating result.